Ketogenic Diet and Neuromodulation in Treatment Resistant Depression

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorSunnybrook Health Sciences Centre

About this trial

The goal of this clinical trial is to test whether combining a ketogenic diet (KD) with personalized, accelerated intermittent theta burst stimulation (iTBS) produces greater reductions in depressive symptoms than iTBS combined with a standard healthy diet in adults with treatment-resistant depression. The trial also aims to determine whether participants can feasibly follow a ketogenic diet during an accelerated iTBS treatment course and whether the diet produces measurable changes in ketone levels.

Specifically, the study aims to determine whether the combined intervention:

1. Reduces depressive symptoms 2. Increases circulating ketone levels 3. Is feasible and tolerable during accelerated iTBS treatment

Participants will begin either a KD or a Canadian Food Guide-aligned diet (CFGD) with a 3-week dietary lead-in period, after which they will undergo a course of personalized, accelerated iTBS while continuing their assigned diet. Before and after the iTBS treatment course, participants will complete clinical assessments, provide blood samples for metabolic testing, and undergo MRI scans to assess brain connectivity. Ketone levels will be measured daily throughout the 12-week dietary intervention. Within-group and between-group differences will be compared to characterize changes in clinical outcomes, metabolism, and brain functioning.

Eligibility criteria

Qualifiers

Age 18-65 of any sex, gender identity, ethnicity and socioeconomic status

Currently experiencing a major depressive episode as defined by DSM-5-TR criteria and confirmed by a study physician

Presenting with at least moderate symptom severity (MADRS ≥ 20)

Meeting criteria for treatment-resistant depression (TRD), defined as non-response to at least two adequate antidepressant trials

Disqualifiers

Medical/psychiatric co-morbidities that prevent participation in the study or where depression is not the primary psychiatric symptom of concern

History of epilepsy, stroke, or major neurological conditions, psychosis, or substance dependence within the last 6 months

Physical or cognitive disability interfering with participation

Females who are pregnant (self-report or via blood work), nursing, or planning a pregnancy during the timespan of the study BMI < 20 kg/m²

Trial design

Treatments tested in this trial

  • Accelerated Intermittent Theta Burst Stimulation (iTBS)

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators